Ramon Velazquez is an assistant professor at the Arizona State University (ASU) School of Life Sciences and a member of the ASU-Banner Neurodegenerative Disease Research Center. He received his doctoral degree at Cornell University in 2014 and worked in the laboratory of Dr. Barbara Strupp. He was funded by the National Science Foundation (NSF) pre-doctoral fellowship as a graduate student and completed his postdoctoral training in molecular biology and neuroscience at ASU, where he was independently funded by the Alzheimer’s Association and via an NSF postdoctoral fellowship. He is the principal investigator and co-investigator of numerous grants from the National Institutes of Health (NIH) and serves as a standing member of the NIH Chronic Dysfunction and Integrative Neurodegeneration study section. He is also the director of the “Workforce Inclusion in Neuroscience through Undergraduate Research Experience” program, to expose underrepresented minorities to research opportunities and neuroscience PhD programs. He is a mPI of a new NIH T32 Program (2024–2029). His research interests include identifying novel therapeutic targets for neurodegenerative disorders such as Alzheimer’s disease (AD), Down Syndrome (DS) and other tauopathies. In particular, he focuses on early molecular events that trigger the progression of these diseases. He is also interested in drug discovery and the dietary supplementation of B-like vitamins to prevent disease progression.
Ramon Velazquez is an assistant professor at the Arizona State University (ASU) School of Life Sciences and a member of the ASU-Banner Neurodegenerative Disease Research Center. He received his doctoral degree at Cornell University in 2014 and worked in the laboratory of Dr. Barbara Strupp. He was funded by the National Science Foundation (NSF) pre-doctoral fellowship as a graduate student and completed his postdoctoral training in molecular biology and neuroscience at ASU, where he was independently funded by the Alzheimer’s Association and via an NSF postdoctoral fellowship. He is the principal investigator and co-investigator of numerous grants from the National Institutes of Health (NIH) and serves as a standing member of the NIH Chronic Dysfunction and Integrative Neurodegeneration study section. He is also the director of the “Workforce Inclusion in Neuroscience through Undergraduate Research Experience” program, to expose underrepresented minorities to research opportunities and neuroscience PhD programs. He is a mPI of a new NIH T32 Program (2024–2029). His research interests include identifying novel therapeutic targets for neurodegenerative disorders such as Alzheimer’s disease (AD), Down Syndrome (DS) and other tauopathies. In particular, he focuses on early molecular events that trigger the progression of these diseases. He is also interested in drug discovery and the dietary supplementation of B-like vitamins to prevent disease progression.